Online citations, reference lists, and bibliographies.
← Back to Search

Positron Emission Tomography In The Diagnosis Of Mesothelioma.

U. Haberkorn
Published 2004 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The increasing incidence of malignant pleural mesothelioma has led to the development of new treatment strategies and a need for new diagnostic techniques to identify the extent of the disease at an early stage and to evaluate treatment. Computed tomography (CT) and magnetic resonance imaging (MRI) are helpful in identifying the location and extent of the involved areas but cannot always differentiate between benign and malignant processes. Fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging, which in oncology, is based on changes in metabolic pathways of glucose, has been shown in a number of studies to differentiate malign and benign lesions in patients with asbestos exposure. FDG-PET images were also found to provide excellent delineation of the active tumour sites. Further evaluations of this technique included a combined experimental/clinical study to investigate the difference in rates of FDG uptake between malignant and inflammatory cells and processes.
This paper references
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.
U. Haberkorn (1991)
Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy.
U. Haberkorn (1993)
10.1007/978-1-4615-1589-0_13
Malignant pleural mesothelioma.
L. Ho (2001)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1016/0006-291X(90)91263-R
Over-expression of facilitative glucose transporter genes in human cancer.
T. Yamamoto (1990)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
F. Bénard (1999)
10.1038/sj.gt.3300679
Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase
U. Haberkorn (1998)
10.1016/0969-8051(94)90162-7
FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models.
U. Haberkorn (1994)
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes.
H. Zhuang (2001)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
[F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes].
I. Buchmann (1999)
10.1053/SONC.2002.30228
The role of imaging in malignant pleural mesothelioma.
E. Marom (2002)



This paper is referenced by
10.1016/S0873-2159(15)30306-8
Mesotelioma. Que há de novo?1
M. L. S. Valente (2008)
10.1097/BRS.0b013e3181ae8294
Malignant Pleural Mesothelioma Presenting as Low Back Pain: Diagnosed by Bone Scan Coordinating With F-18 FDG PET/CT
Y. Huang (2009)
10.1016/S0761-8425(06)71782-X
2.1 Quels critres diagnostiques pour le msothliome pleural malin (MPM)
P. Astoul (2006)
10.1016/J.RADONC.2006.04.007
A novel radiation therapy technique for malignant pleural mesothelioma combining electrons with intensity-modulated photons.
M. Chan (2006)
10.1016/j.ejcts.2008.07.050
Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.
J. Sørensen (2008)
10.1016/S0761-8425(07)78149-4
Prise en charge dignostique et thrapeutique du msothliome pleural malin en 2007
E. Porret (2007)
10.1007/s10269-008-0941-0
Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin en 2008
G. Zalcman (2008)
10.1007/s11307-009-0210-7
Positron Emission Tomography in Mesothelioma Patients
G. Grassetto (2009)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.4046/TRD.2004.57.6.599
A Case of Primary Pericardial Malignant Mesothelioma
D. Kim (2004)
10.2995/JACSURG.30.747
Lymphohistiocytoid mesothelioma of the pleura: A case report
Hideyuki Nishi (2016)
10.1016/j.arcmed.2015.02.002
Malignant Pleural Mesothelioma: Accuracy of CT Against Immunohistochemical Test Among the Mexican Population.
Rodrigo Gopar-Nieto (2015)
10.3892/IJO.28.5.1249
18FDG PET in oncology: the best and the worst (Review).
T. Belhocine (2006)
10.1378/CHEST.129.6.1570
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
F. Giesel (2006)
10.1016/j.remn.2011.06.002
The role of FDG PET-CT in differential diagnosis of pleural pathologies.
U. Elboğa (2012)
Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
V. Ambrosini (2005)
10.1016/J.HOC.2005.09.007
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
Contribution à l'étude de la pathologie pleurale maligne.
B. Duysinx (2009)
10.1007/s11307-009-0212-5
Potential of Dual Time Point FDG-PET Imaging in Differentiating Malignant from Benign Pleural Disease
A. Mavi (2009)
10.1016/J.RMR.2011.09.052
Le suivi post-professionnel des sujets exposés à l’amiante : IRM et TEP-scan☆
M. Carette (2012)
10.1016/J.EJREX.2008.04.006
Radiation-induced liver injury and foreign body reaction secondary to the diaphragmatic Teflon patch in an operated malignant pleural mesothelioma patient: CT, MRI and PET-CT findings
F. Demirkazık (2008)
10.1097/MNM.0b013e32830978c4
Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion
B. Duysinx (2008)
Investigating the role of
C. Stevenson (2011)
10.1007/s11547-006-0034-3
Imaging before and after multimodal treatment for malignant pleural mesothelioma
D. Fiore (2006)
10.1016/J.RCL.2004.09.001
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer.
A. Mavi (2005)
Commentary (Vogelzang/Manno): Update on Malignant Mesothelioma
N. Vogelzang (2005)
10.3769/RADIOISOTOPES.57.33
健康保険適用外の18種類の腫瘍における[18F]FDG-PETの臨床的有用性-多施設アンケート調査による検討-
莞爾 鳥塚 (2008)
10.1097/01.mnm.0000243366.96012.c0
18F-FDG PET imaging in assessing exudative pleural effusions
B. Duysinx (2006)
Semantic Scholar Logo Some data provided by SemanticScholar